Oxymetazoline
Active ingredient · 4 therapeutic classes
Sold as VICKS SINEX MICROMIST · Sinufrin Quick Relief…
- Drug class
- Other Dermatologicals
- Availability
- Over-the-counter
- Routes
- Nasal
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 561
Overview
Plain-language summary, compiled from the cited regulatory records
Oxymetazoline is an active ingredient classified as Other Dermatologicals (D11AX) [1]. It is approved for temporarily relieving nasal congestion caused by the common cold, hay fever, and upper respiratory allergies [1]. Oxymetazoline also temporarily relieves sinus congestion and pressure by shrinking swollen membranes, which helps the user breathe more freely [1].
This ingredient is available under various brand names, including Sinufrin Quick Relief Decongestant [1]. In the past 12 months, there have been 561 adverse event reports associated with this ingredient [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | November 21, 2024 |
| GB United Kingdom | MHRA | 2 | March 27, 2026 |
USUnited States· FDA
3 products
Uses
Uses Temporarily relieves nasal congestion due to: common cold hay fever upper respiroty allergies temporarily relieves sinus congestion and pressure Shrinks swollen membranes so you can breathe more freely
How to take
GBUnited Kingdom· MHRA
2 products
Uses
Oxymetazoline hydrochloride nasal spray is recommended for the relief of nasal congestion in such conditions as the common cold, catarrh and hayfever.
How to take
Drug interactions
Known interactions involving Oxymetazoline. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0c006b1c-8ab2-4b… · revised December 11, 2023 [PDF]
- [2]MHRA (UK) · PL160280049 · revised March 27, 2026
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.